T A B L E O F C O N T E N T S
Considering that none of the current therapeutic options for HAT is optimal in terms of adverse events and ease of administration, it is essential that new anti-trypanosomal compounds are developed and tested in experimental and clinical studies. In the meantime, local availability of the drugs and the status of health facilities and personnel will dictate choice of treatment. It is envisioned that melarsoprol, with its high level of adverse events, will be phased out in favour of eflornithine and NECT. The development of parasite resistance to the drugs needs to be carefully monitored. Future research should also focus on the reduction of the adverse effects of currently used drugs and better diagnostic tests.
B A C K G R O U N D
Human African trypanosomiasis (HAT), or sleeping sickness, is a disease caused by the protozoan parasite Trypanosoma brucei that is transmitted through the bite of infected tsetse flies. The disease occurs throughout sub-Saharan Africa, wherever tsetse flies are found. In 2006, it was estimated that 50,000 to 70,000 individuals were infected (WHO 2006); between 2004 and 2008 , the reported number of new cases was approximately 10,000 (WHO 2009) . The eco-distribution of tsetse flies is determined by the climate, presence of water, vegetation, and their requirement for blood meals (human or animals), but they are mostly found in rural and forested areas. Essential human activities such as farming, collecting water from natural sources, washing, and fishing, can increase contact between humans and tsetse flies and contribute to the spread of the disease (Pepin 2001). The incidence of HAT was reduced to very low levels by the end of the 1950s following large-scale campaigns of active case detection and surveillance, and tsetse flies control campaigns (Cattand 2001) . However, since the 1960s, the gradual breakdown of control programmes, aggravated by economic hardship, war, and civil strife in most endemic countries, resulted in an alarming resurgence of HAT, with epidemics in the Democratic Republic of Congo, Angola, Sudan, Uganda, and the Central African Republic, that resulted in the disruption of whole communities and with huge socioeconomic costs (Seed 2001) . In the past few years the reported number of cases of sleeping sickness has again reduced due to increased control measures, although the exact number of cases is uncertain because of poor health services in most of the affected areas (Brun 2010).
Sleeping sickness is a painful and protracted disease which is almost invariably fatal without adequate treatment; treatment of infected individuals is crucial for reducing the trypanosome reservoir in humans and consequently for controlling the disease. The mostly rural distribution of the disease, civic unrest occurring in many regions affected, the financial and social constraints experienced by endemic countries, and the difficulties in diagnosing and effectively treating HAT, all contribute to make it one of the hardest diseases to control in sub-Saharan Africa.
Two subspecies of Trypanosoma brucei can infect humans. T. b. gambiense causes a generally chronic form of sleeping sickness in West and Central Africa. T. b. rhodesiense, found in Eastern and Southern Africa, generally causes a more acute form of the disease.
In both forms the disease is characterized by two clinical stages related to the propagation of the parasite in the infected host. In the first stage, when trypanosomes multiply in the haemolymphatic system, infected individuals experience intermittent episodes of fever and develop lymphadenopathy, and other non-specific signs such as hepatosplenomegaly and skin rashes (Stich 2002 Treatment for both stages of the disease is also complex. Treatment for the first stage relies on an early diagnosis, often missed due to the lack of specificity of the initial symptoms, and employs two drugs (pentamidine for Gambiense HAT and suramin for Rhodesiense disease) that have been used for more than 60 years and which can produce severe side effects. However, these drugs are still effective and in use (Brun 2010) . In this review we will focus on the treatment of second-stage HAT, which is problematic as drugs available are difficult to administer, and can cause severe adverse events and even death (Chappuis 2007).
Choice of drugs
Treatment of second-stage HAT relies on melarsoprol, eflornithine, or nifurtimox − at present the only anti-trypanosomal compounds that can reach therapeutic levels in the central nervous system. These drugs have been in use for many years, and their in vivo efficacy against HAT has been extrapolated after animal studies or, in the case of nifurtimox, after being used to treat American trypanosomiasis (Chagas disease). Also, the use of any of these drugs is complicated by multiple factors including the increasing incidence of therapeutic failures, painful administration, severe adverse reactions, availability, and high production costs. 
Melarsoprol

O B J E C T I V E S
To evaluate the effectiveness and safety of drugs for treating secondstage HAT.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized and quasi-randomized controlled trials.
Types of participants
• Adults and children with a primary diagnosis of secondstage HAT, that is, having evidence of trypanosomal infection and a CSF analysis showing a WBC count of more than 5 cells/ µL, with no upper limit, and/or the presence of trypanosomes.
• Adults and children relapsing after treatment for secondstage HAT.
Types of interventions
Intervention
Drugs for treating HAT, including melarsoprol, eflornithine, and nifurtimox. Drugs may be given alone, in combination (concomitantly or sequentially), or with an adjunctive treatment.
Control
Other drugs for treating HAT or different regimens of the intervention drugs (eg different dose, frequency, or route of administration).
Types of outcome measures
Primary
• Death during treatment, up to one month after the last drug administration.
• Overall mortality (for any reason, including HAT and treatment toxicity) up to one month after the last drug administration.
• Relapse during follow up: trypanosomes detected in any body compartment (blood, lymph, or CSF) at any follow-up examination (between one and 24 months after the last drug administration); or CSF leukocyte count > 50 WBC/µL CSF, or doubled from previous count, at any follow-up examination; or CSF leukocyte count between 20 and 49 WBC/µL CSF together with symptoms strongly suggestive of relapse (worsened clinical condition since previous examination, with long lasting headache, mental and/or neurological disturbances, increased somnolence, recurrent fever, etc).
Secondary
• Death likely to be due to HAT, up to one month after the last drug administration.
• Relapse: trypanosomes detected in any body compartment (blood, lymph, or CSF) up to one month after the last drug administration.
Adverse events
• Central nervous system adverse events: encephalopathy, seizures, confusion.
• Bone marrow toxicity: anaemia, leucopenia, thrombocytopenia.
• Gastrointestinal symptoms: diarrhoea, nausea and vomit.
• Skin reactions • Infections • Cardiotoxicity.
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).
Databases
We searched the following databases using the search terms and strategy described in (1982 ( to January 2013 and BIOSIS (1926-January 2013) . We also searched the metaRegister of Controlled Trials (mRCT, accessed 11 January 2013) using trypanosom* as the search term.
Conference proceedings
We searched the conference proceedings of The International Scientific Council for Trypanosomiasis Research and Control (ISC-TRC) Conferences for relevant abstracts.
Researchers, organizations, and pharmaceutical companies
We attempted to locate unpublished and ongoing trials by contacting individual researchers working in the field; organizations including Médecins sans Frontières, Epicentre, Malteser, WHO, and TDR.
Data collection and analysis
Selection of studies
All trials identified through systematic literature searches were entered into a database that was screened independently by VL and JS for potentially relevant trials. VL retrieved the full articles of the potentially relevant trials. The three authors together applied the inclusion criteria on the potentially relevant trials using an eligibility form and prepared lists of included and excluded studies. We described the reasons for excluding studies in the 'Characteristics of excluded studies'.
Data extraction and management
VL and AK independently extracted data from the included studies using standardized data extraction forms. JS compared the two data extraction form and prepared a final version. VL entered the data into Review Manager 5. We extracted the number of participants randomized and analysed in each group. For each dichotomous outcome measured, we recorded the number of participants experiencing the event and the number analysed in each group.
Assessment of risk of bias in included studies
VL and AK independently assessed the methodological quality of the included trials using a standardized form. We assessed generation of randomization sequence, allocation concealment, blinding, and loss to follow up. We categorized the generation of allocation sequence and concealment to be adequate, inadequate, or unclear according to Jüni 2001. We assessed which party was blinded in each trial (study investigators, participants, or study assessors). We considered inclusion of 90% or more of the randomized participants in the analysis to be adequate, and less than 90% to be inadequate. Disagreements were resolved by discussion or by reassessment of the data extraction forms by JS. We also attempted to contact the trial authors for any information not specified or unclear.
Data synthesis
VL analysed data using Review Manager 5. Included trials only reported dichotomous outcomes. We did not perform a meta-analysis. Results were presented in forest plots and tables and analysis were stratified by comparisons and by doses/regimens of the drugs.
Measure of effect
We presented outcomes for dichotomous data as risk ratio (RR) with 95% confidence intervals (CI).
Dealing with missing data
We analysed data extracted from the trials on an intention-to-treat basis when there were no missing data, or we used a complete-case analysis, using the number of participants for whom outcomes were reported.
R E S U L T S Description of studies
Our first search in May 2010 identified 25 potentially eligible trials. Sixteen trials were excluded (see 'Characteristics of excluded studies') and nine met the inclusion criteria (see 'Characteristics of included studies'). A second search, for the updated version of this review in January 2013, identified no newly published RCTs but resulted in 2 ongoing trials of interest (DNDi 2012 and DNDi 2012b).
Trial location and participants
All included 
Interventions
Seven trials tested the effectiveness of the currently available drugs to treat second stage HAT: melarsoprol, eflornithine, nifurtimox, used alone or in combination. 
Additional treatments
It is common practice to pre-treat HAT patients against other diseases which are endemic in the same areas, such as malaria and helminthiasis. HAT patients are often treated with prednisolone to reduce the risk of melarsoprol-induced encephalopathy, and in some of the included trials they received multivitamins, paracetamol or food rations (also given to their accompanying carers as hospitals and health centres in the endemic areas don't usually have enough resources to provide food). We have listed the details of the additional treatments for each trials in a separate table (Table  1) .
Dosing and regimens
Melarsoprol monotherapy
Melarsoprol was always used intravenously; dosages and schedules tested varied between studies. A "standard regimen" (three series of 3.6 mg/kg/day for three days, with a seven day break between series for a total duration of 26 days) was used in Bisser 2007 and Pepin 2006. A shorter schedule of melarsoprol at 2.2 mg/kg/day for 10 days was used by Burri 2000, in comparison with a "standard Angolan schedule" over 26 days as follows: 1.2 mg/kg on day one, 2.4 mg/kg on day two, 3.6 mg/kg on day three and four, repeated on days 12-15 and 23-26. A 10 day schedule of melarsoprol at 2.16 mg/kg/day was used by Pepin 2006. Incremental melarsoprol was also used by Bisser 2007 at doses from 0.6 mg/kg to 1.8 mg/ kg for the first three days, followed by the same dose of 1.8 mg/kg/ day until day 10, and by Pepin 2006 where the doses started at 1.8 mg/kg up to 3.6 mg/kg for three series of three injections separated by seven days. Pepin 1989a used a 3.6 mg/kg dose of melarsoprol but the number of series and injections varied according to the white blood cell count of the patient -this is known as a Neujean schedule.
Nifurtimox monotherapy
Nifurtimox was administered orally at 5 mg/kg every eight hours for 10 days in Bisser 2007.
Eflornithine monotherapy
Oral eflornithine was tested in Na-Bangchang 2004 comparing doses of 400 mg/kg/day with 500 mg/kg/day. Pepin 2000 compared intravenous eflornithine (which is given a slow infusion) at 400 mg/kg/day for seven compared with 14 days in a trial including new and relapsing patients. Priotto 2009 tested eflornithine only given a slow infusion at 400 mg/kg/day for 14 days against the combination of nifurtimox-eflornithine described below.
Pentamidine monotherapy
Pentamidine was used in Lejon 2003 at a dose of 4 mg/kg for 10 days, given intramuscularly, for patients in the so-called intermediate stage (ie with a CSF cell count between 6 and 20 cells/µL).
Combination therapies
1) Melarsoprol-nifurtimox low-dose combination (Bisser 2007) for 10 days: melarsoprol alone at 0.6 mg/kg intravenously on day one and at 1.2 mg/kg intravenously on day two, followed by eight days of oral nifurtimox at 7.5 mg/kg every twelve hours, combined with melarsoprol at 1.2 mg/kg intravenously/day. 2) Melarsoprol-nifurtimox was used in Priotto 2006 at doses of 1.8 mg/kg/day intravenous melarsoprol for 10 days, and oral nifurtimox at 15 mg/kg/day every eight hours for 10 days.
3) Melarsoprol-eflornithine (intravenous melarsoprol , eflornithine as slow infusion) was used in Priotto 2006: melarsoprol at 1.8 mg/kg/day for 10 days, eflornithine at 400 mg/kg/day, every six hours for seven days. 4) Melarsoprol + prednisolone (Pepin 1989a) added oral prednisolone at 1 mg/kg/day, given at intervals, to a Neujean schedule of melarsoprol. 5) Nifurtimox-eflornithine was used in Priotto 2006 and in Priotto 2009 as oral nifurtimox at 15 mg/kg/day every eight hours for 10 days, added to eflornithine as a slow infusion at 400 mg/kg/day, every six hours for 7 days (Priotto 2006) or every 12 hours for seven days (Priotto 2009).
Outcome measures
The included trials measured different outcomes from our protocol: most trials did not differentiate between death due to the disease or due to treatment (encephalopathy caused by melarsoprol), and measured death related to treatment or within 30 days of ending it. Parasitological cure rates (trypanosomes in any body compartment) were measured usually within one day from the end of treatment. 
Risk of bias in included studies
We included nine randomized controlled trials. See ' Characteristics of included studies' for details, also Figure 1 and Figure 2 . 
Effects of interventions
All adverse events described below are also listed in Table 2 .
Melarsoprol monotherapy: dosages and regimens
Graded 26 days (Angolan schedule) versus fixed 10 days
Burri 2000 compared these regimens in two groups of 250 participants. There were no significant difference between the groups death during treatment (six in each group; Analysis 1.1), but the overall mortality was higher in the Angolan scheme: 12 versus 9; RR 1.33, 95% CI 0.57 to 3.11. The same number of participants in both groups (14/250) developed encephalopathy and there were no differences in the number of diarrhoea cases in the two groups of participants (17 and 18 respectively; Table 2 ). Participants treated for 10 days experienced a higher number of skin reactions (39/ 250 versus 15/250 for the 26 days schedule; Table 2 ). Number of relapses during follow up were higher in the Angolan scheme (5 versus 3) but not significantly different (RR1.67, 95% CI 0.40 to 6.90 Analysis 1.3)
Standard (3.6 mg) versus graded 26 days
In Pepin 2006 a standard dose of melarsoprol was compared to a graded dose, both given for 26 days. The group of participants receiving the standard dose had a lower risk of death during treatment (RR 0.47, 95% CI 0.12 to 1.82; Analysis 1.1) and a lower number of seizures (7/149 compared to 7/70 for graded melarsoprol). As the clinical team was not blinded, enrolment in the graded melarsoprol arm was stopped early.
Standard (3.6 mg) versus incremental 10 days
Bisser 2007 found higher overall mortality (9/70) in the group that received incremental melarsoprol for 10 days than in the group of patients treated with standard melarsoprol (5/69, Analysis 1.2). The risk of relapse during follow-up was lower in the standard melarsoprol group (RR 0.42, 95% CI 0.18 to 0.94; Analysis 1.3). Numbers of participants suffering encephalopathy, diarrhoea, nausea and vomiting were similar in the two groups but the longer standards schedule resulted in more phlebitis 19/69 versus 13/70 (see Table 2 ).
Standard melarsoprol (3.6 mg) versus fixed 10 days
Pepin 2006 evaluated the effectiveness of a standard dose of melarsoprol given over 26 days compared with a shorter regimen of 10 consecutive daily injections, finding that the frequency of death during treatment did not vary significantly (4/149 for the standard dose versus 6/170 for the 10 days regimen, Analysis 1.1). The number of neurological adverse events (seizures, confusion) was also similar in the groups (see Table 2 ) but the group receiving a shorter schedule had more skin reactions (6/170 versus only 1/ 149 in the standard melarsoprol group).
Graded 26 days versus fixed 10 days
Pepin 2006 reported that the frequency of death during treatment was not significantly different between groups receiving the two treatments (Analysis 1.1). Seizures were more frequent in the participants receiving graded melarsoprol (7/70) than in those receiving the fixed 10-day schedule (4/170). Skin reactions were experienced with the shorter schedule (6/170).
Eflornithine monotherapy: dosages and regimens
Different regimens for eflornithine monotherapy were tested in two trials. Pepin 2000 compared the same dose of 400 mg/kg/day, given as a slow intravenous infusion every six hours, for seven or 14 days, in groups of patients recruited from four different sites. Participants treated for seven days had lower risk of death during treatment (RR 0.21, 95% CI 0.02 to 1.75) than those on the 14-day schedule (Analysis 2.1), and fewer of them suffered gastrointestinal symptoms (Table 2 ), but the shorter schedule resulted in more relapses during follow up (28/158 against 14/163; RR 2.06, 95% CI 1.13 to 3.77 Analysis 2.3). Na-Bangchang 2004 used eflornithine orally, as this may constitute a more convenient way of administration than the slow intravenous infusion, and compared two doses of 500 and 400 mg/kg/ day in two small groups of participants (13 and 12).There were no deaths in the two groups, and rates of relapse (Analysis 2.3) and adverse events (diarrhoea, anaemia, leukopenia) were similar.
Comparisons between single drugs (monotherapies)
Melarsoprol (standard 3.6 mg) versus nifurtimox (14 days)
This comparison was tested by Bisser 2007. The frequency of death during treatment or overall mortality was not significantly different in the two groups (Analysis 3.1 and Analysis 3.2), but patients receiving melarsoprol had fewer relapses during follow up (RR 0.30, 95% CI 0.14 to 0.64; Analysis 3.3). Encephalopathy was more frequent in the melarsoprol group (4/69 participants) than in the nifurtimox group (1/70), and experienced a high number of infections (phlebitis; 19/69), but participants receiving nifurtimox had more gastrointestinal symptoms such as nausea and vomiting.
Melarsoprol (incremental 10 days) versus nifurtimox (14 days)
This comparison was tested in Bisser 2007 in two groups of 70 participants each. There was no difference in the number of deaths during treatment (three in each group), but the overall mortality was much lower in the nifurtimox group -three versus nine (RR 0.33, 95% CI 0.09 to 1.18; Analysis 3.2), while the number of relapses was higher in participants who has received nifurtimox (24/70) than in those treated with melarsoprol (17/70; Analysis 3.3). Participants in the melarsoprol group had a high number of phlebitis (13/70; Table 2 ).
Melarsoprol (standard (graded)) versus pentamidine
Lejon 2003 compared melarsoprol with pentamidine, which is more commonly used for first stage HAT, in participants with 20 or fewer cells in CSF. The only reported outcome is relapse, which was more frequent in participants treated with pentamidine (Analysis 3.4). No adverse events were recorded.
Combination therapies
Melarsoprol versus melarsoprol + prednisolone
In Pepin 1989a, a Neujean schedule of melarsoprol was compared to the same schedule with added oral prednisolone. The differences in the number of deaths and relapses in the two groups were not statistically significant (Analysis 4.2 and Analysis 4.4), but participants who received melarsoprol only had a much higher number of encephalopathies (35/308) compared with those who also received prednisolone (12/290; Table 2 ).
Melarsoprol (standard 3.6 mg) versus melarsoprolnifurtimox (10 days)
There was no statistically significant difference in the number of deaths between the two groups of 69 participants each, but participants treated with melarsoprol-nifurtimox had no relapses compared with seven occurring in the melarsoprol group (RR 0.07, 95% CI 0.00 to 1.15; Analysis 4.4) lower numbers of encephalopathy cases (2/69 versus 4/69 for standard melarsoprol), and lower numbers of phlebitis (6/69 versus 19/69; Table 2 ).
Melarsoprol (incremental 10 days) versus melarsoprolnifurtimox
Bisser 2007 reported no relapses in the group of participants who received the combination of melarsoprol and nifurtimox (RR 0.03, 95% CI 0.00 to 0.47; Analysis 4.4); differences in the number of deaths during treatment were not significant (Analysis 4.2). Melarsoprol-nifurtimox also reduced the number of encephalopathies (2/69 versus 5/70), and of phlebitis (6/69 versus 13/70; Table 2 ) but the two groups had similar numbers of gastrointestinal symptoms.
Nifurtimox (14 days) versus melarsoprol-nifurtimox
Melarsoprol-nifurtimox was compared to nifurtimox monotherapy in Bisser 2007: there were no relapses in the 69 participants receiving the drug combination (RR 0.02, 95% CI 0.00 to 0.33; Analysis 4.4). Overall mortality was higher in the melarsoprol-nifurtimox group of participants (6/69 versus 3/70 deaths; Analysis 4.3), who also reported two cases of encephalopathy against only one case in the nifurtimox group, and six cases of phlebitis (Table  2) . Participants treated with nifurtimox alone had slightly more nausea and vomiting (Table 2) .
Eflornithine versus eflornithine-nifurtimox
Priotto 2009 compared eflornithine monotherapy given every six hours for 14 days, with a eflornithine-nifurtimox combination (eflornithine given every 12 hrs for seven days + oral nifurtimox for 10 days). The results (Analysis 4.2; Analysis 4.3; Analysis 4.4) show that although number of deaths were similar, there were more relapses during follow-up in the eflornithine group. Participants treated with eflornithine-nifurtimox had more seizures (18/ 143) than those receiving eflornithine only (13/143), and also experienced more nausea and vomiting (69/143 versus 29/143), but they did not experience diarrhoea and also had fewer cases of neutropenia (2/143 versus 10/143). Eflornithine caused more infections and more skin reactions when used alone than when combined with nifurtimox (Table 2 ).
Eflornithine-nifurtimox versus melarsoprol-eflornithine
Priotto 2006 evaluated this comparison in two relatively small groups of participants (17 and 19 respectively). There were significantly fewer deaths in the group treated with eflornithine-nifurtimox (RR 0.37, 95% CI 0.02 to 8.53 for deaths during treatment; (Analysis 4.2); RR 0.37, 95% CI 0.04 to 3.25 for overall mortality, (Analysis 4.3). The risk of relapse during follow up was significantly smaller for participants treated with eflornithinenifurtimox (RR 0.28, 95% CI 0.03 to 2.26,( Analysis 4.4). The eflornithine-nifurtimox group reported more seizures (4/17) and more participants developed neutropenia (3/17) than in the melarsoprol-eflornithine group; however the latter had more gastrointestinal symptoms (see Table 2 ).
Eflornithine-nifurtimox versus melarsoprol-nifurtimox
There was a significant lower risk of death during treatment (RR 0.12, 95% CI 0.01 to 2.03, Analysis 4.2), overall mortality (RR 0.15, 95% CI 0.02 to 1.10, Analysis 4.3), and relapse during follow up (RR 0.11, 95% CI 0.02 to 0.74, Analysis 4.4) in the group of participants treated with eflornithine-nifurtimox. The two groups reported similar number of adverse events (seizures, gastrointestinal symptoms; Table 2 ), but more eflornithine-nifurtimox participants developed neutropenia (3/17 versus 0/18).
Melarsoprol-eflornithine versus melarsoprol-nifurtimox
There were fewer deaths during treatment (RR 0.24, 95% CI 0.03 to 1.92, Analysis 4.2), less overall mortality (RR 0.41, 95% CI 1.12 to 1.33, Analysis 4.3), and fewer relapses (RR 0.38, 95% CI 0.14 to 0.99, Analysis 4.4) in the group that received melarsoprol-eflornithine. Twice as many participants in the melarsoprolnifurtimox group had seizures (4/18) but fewer developed diarrhoea, nausea, and vomiting than those treated with melarsoproleflornithine (Table 2) . Only one participant in the melarsoproleflornithine group suffered neutropenia. Some aspects of the methodological quality of most trials were not optimal, but this was related to the characteristics of the treatment under investigations. The different routes of administration and regimes under comparison would not have allowed blinding of participants and medical personnel in any of the trials. Allocation concealment and randomization methods however were adequate and well described in most trials. Furthermore, the priority in the past was mainly to treat the enormous existing number of patients in order to be able to control the disease; we did not include studies which were not randomized, but many of these excluded publications reported on important medical observations. This applies in particular to T. b. rhodesiense second-stage disease in which no randomized controlled trials were found. Rhodesiense HAT tends to occur in self-limited epidemic outbreaks or as isolated cases, and the reported cases represent less than 10% of all HAT cases (Simarro 2008).
D I S C U S S I O N
1) Monotherapies -melarsoprol and eflornithine
Melarsoprol can induce a life-threatening encephalopathy in a large percentage of treated patients (Seixas 2005) and trials assessing melarsoprol have been aimed at minimizing doses of the drug and length of treatment while maintaining anti-trypanosome activity. did not report differences in outcomes or adverse events between the graded schedule and the 10-day schedule, the other two trials showed that graded or incremental melarsoprol resulted in higher death rates, higher number of seizures (Pepin 2006) and more relapses (Bisser 2007) , suggesting that incremental melarsoprol schedules should be abandoned (Pepin 2006) .
A large multinational non-randomized clinical study (Schmid 2005) also confirmed the effectiveness (non-inferiority) of the shorter 10-day melarsoprol schedule, in comparison with the standard 26 days of treatment, with regard to cure rates and adverse events. The applicability of this abridged 10-day melarsoprol schedule to Rhodesiense HAT patients has recently been tested in a utilization study in two trial centres in Uganda an Tanzania  (IMPAMEL IIII) , showing similar levels of adverse events with historical controls. The potential implementation of this abridged melarsoprol schedule to second stage Rhodesiense HAT patients is currently being evaluated, but the trial was non-randomized and outside the inclusion criteria of this review.
Pepin 1989a showed that the addition of prednisolone to melarsoprol reduced the number of encephalopathy cases and associated mortality. Prednisolone and other corticosteroids had been used as an adjunctive treatment to melarsoprol for many years but this was the first randomized trial to test it and indicate its effectiveness. This trial is however of insufficient methodological quality (Figure 1 ). Prednisolone and prednisone are currently still in use in patients receiving melarsoprol as no suitable alternative encephalopathic syndrome preventive treatment has been identified, but their effectiveness remains unclear.
Eflornithine is effective against T. b. gambiense and induces less severe adverse events than melarsoprol, but it has to be administered as a slow intravenous infusion every six hours and this is difficult under field conditions. Pepin 2000 tested a 7-day against a 14-day regimen and showed that treating for seven days resulted in fewer deaths and fewer adverse events in patients relapsing from a previous episode of sleeping sickness, making it a suitable alternative in this kind of patient. The 7-day regimen was however less effective than the 14-day schedule especially for new cases. Na-Bangchang 2004 tested oral eflornithine at two slightly different dosages (500 and 400 mg/kg/day). There were no deaths in this trial, and similar levels of adverse events between the two patient groups, but oral eflornithine seemed not to reach adequate levels in plasma and CSF, and further development of this administration route was abandoned.
3) Comparisons between single drugs
Bisser 2007 tested two melarsoprol regimens, a standard 26-day regimen and an incremental 10-day regimen, against nifurtimox. The two melarsoprol regimens were more effective at preventing relapses than nifurtimox alone, but induced more cases of encephalopathies, and overall mortality was highest with incremental melarsoprol.
Melarsoprol also gave fewer relapses than pentamidine (Lejon 2003) but no other outcomes or adverse events were reported in this trial. The results of this trial indicate that the use of pentamidine (commonly used for first stage HAT) in patients in the socalled intermediate stage is hazardous and that better markers of disease stage are needed to allow its safe use in this clinical situation.
4) Combination therapies
Since 2006, two-drugs combinations between any of the drugs used in second-stage HAT (melarsoprol, eflornithine and nifurtimox) have been tested in randomized controlled trials.
Bisser 2007 tested a combination of melarsoprol and nifurtimox, given for 10 days, against standard or incremental melarsoprol regimens, and against nifurtimox alone, in an equivalence trial. Melasorprol-nifurtimox was more effective than monotherapies at reducing the number of relapses but adverse events were comparable between groups and encephalopathies were reported in all regimens which included melarsoprol.
A trial testing comparing melarsoprol-nifurtimox with melarsoprol-eflornithine and nifurtimox-eflornithine had to be interrupted because of the high number of deaths, due to reactive encephalopathy, reported in the melarsoprol-nifurtimox group (Priotto 2006) . The same trial showed that patients receiving nifurtimox-eflornithine had a lower risk of relapse and fewer deaths than those receiving drug combinations with melarsoprol. Following this initial observation a much larger multi-site trial to compare eflornithine with nifurtimox-eflornithine (thus completely removing melarsoprol) was planned, implemented in selected HAT treatment centres and recently completed (Priotto 2009). The combination of nifurtimox and eflornithine (NECT) was shown to give fewer relapses and was generally well tolerated. A satisfactory safety profile of NECT was confirmed in a non-randomized study in the Democratic Republic of Congo, which included children and pregnant women (Schmid 2012), and in a recent cohort study (Alirol 2013) which also included children . A major advantage of NECT is the reduction in the frequency and number of eflornithine slow infusions to twice a day, thus reducing the burden on health personnel and patients alike. Priotto 2009 was designed as a non-inferiority trial and its clinical results confirmed the noninferiority of NECT to eflornithine alone; other considerations are the practical advantages of using NECT in terms of drug quantities, personnel time and logistic costs. Furthermore, the combined use of two drugs should decrease the emergence of resistance.
Future perspectives
NECT was approved by the Expert Committee on the Selection After several decades of scarce attention, the past few years have seen a new impetus in the fight against HAT, due in good part to an efficient co-ordination and collaboration between different agencies, researchers, and national trypanosomiasis programmes, the diminution of social upheavals, capacity building activities and the free provision of diagnostic and reagents and medicines. The situation has improved even in the few years since the protocol for this Cochrane review was first published (2006): the total number of HAT cases decreased 68% between 1995 and 2006 (Simarro 2008 . Clinical trials of high methodological quality have been completed since then (despite no significant reduction in the logistic challenges to be faced by trialists). So the practical implications of these latest trials go beyond their clinical results to also include a framework for planning and executing trials in resourcepoor settings.
There are signs that the use of melarsoprol will decline. An analysis of pooled data from 11,668 patients from different countries showed that its effectiveness was lower than eflornithine (Balasegaram 2009). In the absence of a direct randomized comparison between melarsoprol, eflornithine and NECT, this is a relevant finding due to the number of patients treated from several different locations and a comprehensive analysis of the outcomes. Also, although the choice of HAT therapy is often dictated by local conditions of availability, active public-private partnerships have allowed Gambiense HAT endemic countries to increase the use of eflornithine and NECT, resulting in a decrease in the percentage of melarsoprol treated patients from 86% in 2004 86% in to 51% in 2008 86% in (WHO 2009 ). Parasite resistance is less likely to develop with a combination such as NECT, but a system of monitoring will be needed to monitor the effectiveness of drug regimens over time.
It is imperative that studies on the reduction of the adverse ef-fects of currently used drugs, testing different regimens, and experimental and clinical studies on the development of new antitrypanosomal compounds, effective for both stages of the disease, also continue taking place.
A U T H O R S ' C O N C L U S I O N S Implications for practice
Choice of therapy for second stage Gambiense HAT in the next few years will continue to be dictated by local conditions of availability and logistic difficulties, but it is envisioned that melarsoprol, with its high level of adverse events, will be phased out in favour of eflornithine and NECT. Parasite resistance to the drugs as well as their effectiveness need to be carefully monitored in large cohort studies.
Implications for research
It is essential that future research focus on the reduction of the adverse effects of currently used drugs, tests on different regimens, and experimental and clinical studies on the development of new anti-trypanosomal compounds, effective for both stages of the disease. Development of new diagnostic tools, both to improve disease confirmation and to precisely determine the stage of the disease, and to avoid the need for lumbar punctures performed under unsafe conditions, is also necessary.
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